Core Insights - LIXTE Biotechnology Holdings has received a Notice of Allowance for a patent related to combining its LB-100 compound with various cancer immunotherapies, enhancing its intellectual property portfolio [1][2][5] - The company is conducting clinical trials for LB-100 in combination with immunotherapies at notable institutions, including the Netherlands Cancer Institute and MD Anderson Cancer Center [3][4] - LIXTE's LB-100 is positioned as a first-in-class PP2A inhibitor, which is being tested for its potential to improve cancer treatment outcomes [6][7] Patent and Intellectual Property - The newly awarded patent supports LIXTE's commitment to innovative cancer research and treatment solutions [2] - An exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and the National Cancer Institute allows LIXTE to explore novel combination therapies [5] Clinical Trials and Research - LB-100 is being tested in combination with Roche's atezolizumab for metastatic colon cancer and GSK's dostarlimab-gxly for ovarian clear cell carcinoma [4] - The company is advancing a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept trials for various cancer types [7]

-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company- -Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer- -Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy- -LIXTE to Present at Two Upcoming Investor Conferences- PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical-s ...

-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference; and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference- PASADENA, CALIF., Aug. 15, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will be presenting at two investor conferences: The Investor Summit Summer 2024 Virtual Conference Tuesday, August 20, 2024, at 2 p.m. EDT/11 a.m. PDT. ...

Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system "This is an exciting new clinical trial," said Neeltje Steeghs, M.D., Ph.D., medical oncologist from NKI and Antoni van Leeuwenhoek Hospital, who is serving as principal investigator of the trial. "Only about 15% of colon cancers are responsive to immunotherapy, the so-called MSI High cancers. However, approximately 85% of colon cancers are MSI Low where i ...

PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer. NKI is one of the world's leading comprehensive cancer centers. René Bernards, Ph.D., a leader in the field of molecular carcinogenesis and Senior Staf ...

PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced a collaboration with Roche and the Netherlands Cancer Institute (NKI) to conduct a new clinical trial in immune therapy unresponsive (MSI Low) metastatic colon cancer. "This is an exciting new clinical trial," said Neeltje Steeghs, M.D., Ph.D., medical oncologist from the Netherlands Cancer Institute, who is serving a ...

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced online publication of new pre-clinical data in the journal EMBO Reports, showing that its lead compound, LB100, can turn immunologically "cold" tumors "hot," potentially enhancing the benefit ...

PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical stage pharmaceutical company, today announced online publication of new pre-clinical data in the journal EMBO Reports, showing that its lead compound, LB-100, can turn immunologically "cold" tumors "hot," potentially enhancing the benefit of immunotherapy. The current publication is a peer-reviewed version of a preprint that was previously made available in July 2023 to bio ...

PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today announced the appointment of Jan Schellens, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Schellens brings to LIXTE more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including mo ...

Publishing of Findings in Recent Pre-Clinical Study for LIXTE's Proprietary Compound, LB-100, in New Field of Cancer Biology, "Activation Lethality" Presentation at MedInvest Biotech and Pharma Investor Conference Co-Sponsorship/Presentation of Workshop at Harvard University's Dana Farber Cancer Institute PASADENA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of canc ...